The medical management of men with castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade.
Men can now access several agents developed to extend survival, delay morbidity caused by complications, and preserve quality of life. Strategies to extend survival include docetaxel and cabazitaxel, the CYP-inhibitor abiraterone acetate, the second-generation androgen receptor antagonist enzalutamide, sipuleucel-T immunotherapy, and the α-emitting radionuclide (223)radium. These novel therapies have fostered interest in translational science and a deeper understanding of the underlying biology of CRPC. This article summarizes clinical data and unresolved issues in the use of current and emerging CRPC therapies.
Written by:
Pezaro C, Omlin A, Lorente D, de Bono J. Are you the author?
Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
Reference: Hematol Oncol Clin North Am. 2013 Dec;27(6):1243-60.
doi: 10.1016/j.hoc.2013.08.008
PubMed Abstract
PMID: 24188261
UroToday.com Prostate Cancer Section
